Corticosteroid

With dozens of topical therapies and systemic treatments available for atopic dermatitis, clinicians have many options. But a pair of reviews in The Journal of Allergy and Clinical Immunology may help them narrow down their choices.

The most burdensome adverse events that patients with asthma reported when using inhaled and oral corticosteroids did not always cause them to stop therapy, according to a study published in Annals of Allergy, Asthma & Immunology.

HONOLULU — Children with uncontrolled moderate to severe asthma experienced fewer severe exacerbations requiring systemic corticosteroids when treated with dupilumab, according to a poster presented at the CHEST Annual Meeting.

Many patients with moderate to severe asthma failed to use inhaled corticosteroids in addition to a short-acting beta 2 agonist as a rescue to prevent exacerbations, according to a study published in Annals of Allergy, Asthma & Immunology.

Exposure to intranasal corticosteroids did not have any adverse impact on COVID-19 mortality among a general population or among patients with asthma or COPD, according to a study published in Annals of Allergy, Asthma & Immunology.

Black children were more likely to require EMS and receive bronchodilator treatment for an asthma episode than white children, but were less likely to receive EMS transport, according to a study published in Prehospital Emergency Care.

The Allergy-Immunology Joint Task Force on Practice Parameters has issued guidelines for the medical management of chronic rhinosinusitis with nasal polyps, according to a review published in Annals of Allergy, Asthma & Immunology.

EP-104AR, an injectable form of fluticasone propionate designed slowly distribute through the knee joint and provide pain relief for up to 6 months, improved pain vs. a placebo over 12 weeks, according to the manufacturer.

Patients with asthma preferred convenient management options that prioritized decreases in short-term morbidity over long-term goals, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

Among patients with pulmonary sarcoidosis, efzofitimod was safe through 24 weeks, and it improved measures of lung function and quality of life when given at a higher dosage, according to study results published in CHEST.